Dexcom Expands Operations in Lithuania with New Clinical Affairs Team

Dexcom, a global leader in continuous glucose monitoring (CGM) technology, is expanding its Clinical Affairs team to Lithuania. The expansion reflects the company’s commitment to broadening its clinical research efforts within Europe. The new hires will join Dexcom’s 500-strong team at the company’s Global Business Services hub in Vilnius. 

The decision to expand follows a visit earlier this year by Dexcom’s global clinical research leadership team, who evaluated Lithuania’s potential to manage clinical studies for EMEA and US. As a result, Dexcom plans to hire specialized professionals for roles directly focused on clinical research, ranging from compliance and data analysis to clinical trial management. These new employees will play a key role in managing Clinical trials and internal product research at Dexcom’s Vilnius office. 

The Clinical Affairs team will include positions such as Senior Clinical Research Associate, Senior Quality Compliance Specialist, and Clinical Program Manager. These roles require expertise in Good Clinical Practice (GCP), regulatory compliance, and advanced data management systems – skills abundant in Lithuania’s growing life sciences sector. 

Historically, Dexcom’s clinical trials have been concentrated in the United States. However, the company is now shifting its focus to Europe as part of its global growth strategy. Dexcom’s Vilnius office, which opened in 2020, provides fertile ground for expanding the company’s clinical research efforts. 

In Lithuania, Dexcom actively collaborates with leading educational institutions such as Vilnius University, Kaunas University of Technology, and Vilnius Coding School through career fairs and various talent acquisition initiatives. As part of its commitment to community engagement and social responsibility, the company also partners with local organizations like Diabitė, a Lithuanian children’s diabetes club. 

Headquartered in San Diego, California, Dexcom develops and markets continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes. The company employs approximately 10,000 people across offices in the US, Europe, and Asia Pacific.